Although NRF2 regulates the transcription of genes involved in GSH synthesis, and could protect some cancer cells from ferroptosis [21–23], here we provide evidence that NRF2 expression is a poor predictor of ferroptotic sensitivity for glioblastoma cells since the role of NRF2 in ferroptosis could be actually determined by MRP1, which counterbalances the protective effects of GSH synthesis by NRF2. Indeed, it was recently demonstrated that NRF2 expression, as well as basal intracellular total GSH, are not sufficient to predict the sensitivity to ferroptosis in HAP1 cells [24]. This evidence concerns the gene NFE2L2 and glioblastoma.